Evidence map›Paper›PMID 38989579›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2024

Synergy Between NK Cells and Monocytes in Potentiating Cardiovascular Disease Risk in Severe COVID-19.

Manuja Gunasena, Mario Alles, Yasasvi Wijewantha, Will Mulhern, Emily Bowman, Janelle Gabriel, Aaren Kettelhut, Amrendra Kumar, Krishanthi Weragalaarachchi, Dhanuja Kasturiratna and 10 more

Abstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Manuja Gunasena *Department of Microbial Infection and Immunity, College of Medicine (M.G., M.A., Y.W., W.M., K.W., S.-L.L., N.P.M.L.), The Ohio State University, Columbus.ORCID 0000-0002-0059-6540
Mario Alles *Department of Microbial Infection and Immunity, College of Medicine (M.G., M.A., Y.W., W.M., K.W., S.-L.L., N.P.M.L.), The Ohio State University, Columbus.
Yasasvi Wijewantha *Department of Microbial Infection and Immunity, College of Medicine (M.G., M.A., Y.W., W.M., K.W., S.-L.L., N.P.M.L.), The Ohio State University, Columbus.
Will MulhernDepartment of Microbial Infection and Immunity, College of Medicine (M.G., M.A., Y.W., W.M., K.W., S.-L.L., N.P.M.L.), The Ohio State University, Columbus.
Emily BowmanSchool of Health and Rehabilitation Sciences, College of Medicine (E.B., J.G., A. Kettelhut., N.T.F.), The Ohio State University, Columbus.
Janelle GabrielSchool of Health and Rehabilitation Sciences, College of Medicine (E.B., J.G., A. Kettelhut., N.T.F.), The Ohio State University, Columbus.
Aaren KettelhutSchool of Health and Rehabilitation Sciences, College of Medicine (E.B., J.G., A. Kettelhut., N.T.F.), The Ohio State University, Columbus.
Amrendra KumarDepartment of Pathology, College of Medicine (A. Kumar, S.S., A.V.), The Ohio State University, Columbus.
Krishanthi WeragalaarachchiDepartment of Microbial Infection and Immunity, College of Medicine (M.G., M.A., Y.W., W.M., K.W., S.-L.L., N.P.M.L.), The Ohio State University, Columbus.
Dhanuja KasturiratnaDepartment of Mathematics and Statistics, Northern Kentucky University, Highland Heights (D.K.).ORCID 0000-0003-1370-6590
Jeffrey C HorowitzDepartment of Internal Medicine, College of Medicine (J.C.H., S.R.P., J.S.B.), The Ohio State University, Columbus.ORCID 0000-0002-1505-2837
Scott ScrapeDepartment of Pathology, College of Medicine (A. Kumar, S.S., A.V.), The Ohio State University, Columbus.
Sonal R PannuDepartment of Internal Medicine, College of Medicine (J.C.H., S.R.P., J.S.B.), The Ohio State University, Columbus.
Shan-Lu LiuDepartment of Microbial Infection and Immunity, College of Medicine (M.G., M.A., Y.W., W.M., K.W., S.-L.L., N.P.M.L.), The Ohio State University, Columbus.ORCID 0000-0003-1620-3817
Anna VilgelmDepartment of Pathology, College of Medicine (A. Kumar, S.S., A.V.), The Ohio State University, Columbus.
Saranga WijeratneThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH (S.W.).ORCID 0000-0002-9782-4406
Joseph S BednashDepartment of Internal Medicine, College of Medicine (J.C.H., S.R.P., J.S.B.), The Ohio State University, Columbus.ORCID 0000-0003-3576-4388
Thorsten DembergDepartment of Pediatrics, Baylor College of Medicine, Houston, TX (T.D.).ORCID 0000-0002-7799-6876
Nicholas T FunderburgSchool of Health and Rehabilitation Sciences, College of Medicine (E.B., J.G., A. Kettelhut., N.T.F.), The Ohio State University, Columbus.
Namal P M LiyanageDepartment of Microbial Infection and Immunity, College of Medicine (M.G., M.A., Y.W., W.M., K.W., S.-L.L., N.P.M.L.), The Ohio State University, Columbus.ORCID 0000-0001-7362-3282

Funding

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4M
Institutional Career Development CoreKL2TR002734 · NCATS · OHIO STATE UNIVERSITY · PI CARNES, CYNTHIA A · 2018 to 2022
$2.7M
Combining senescence-inducing and senolytic agents to improve melanoma therapyR37CA233770 · NCI · VANDERBILT UNIVERSITY · PI VILGELM, ANNA E · 2019 to 2025
$2.4M
NCATS NIH HHS KL2 TR002734NCATS NIH HHS UL1 TR002733NCI NIH HHS R37 CA233770NCI NIH HHS U54 CA260582
6 · The paper itself

Abstract

backgroundEvidence suggests that COVID-19 predisposes to cardiovascular diseases (CVDs). While monocytes/macrophages play a central role in the immunopathogenesis of atherosclerosis, less is known about their immunopathogenic mechanisms that lead to CVDs during COVID-19. Natural killer (NK) cells, which play an intermediary role during pathologies like atherosclerosis, are dysregulated during COVID-19. Here, we sought to investigate altered immune cells and their associations with CVD risk during severe COVID-19.

methodsWe measured plasma biomarkers of CVDs and determined phenotypes of circulating immune subsets using spectral flow cytometry. We compared these between patients with severe COVID-19 (severe, n=31), those who recovered from severe COVID-19 (recovered, n=29), and SARS-CoV-2-uninfected controls (controls, n=17). In vivo observations were supported using in vitro assays to highlight possible mechanistic links between dysregulated immune subsets and biomarkers during and after COVID-19. We performed multidimensional analyses of published single-cell transcriptome data of monocytes and NK cells during severe COVID-19 to substantiate in vivo findings.

resultsDuring severe COVID-19, we observed alterations in cardiometabolic biomarkers including oxidized-low-density lipoprotein, which showed decreased levels in severe and recovered groups. Severe patients exhibited dysregulated monocyte subsets, including increased frequencies of proinflammatory intermediate monocytes (also observed in the recovered) and decreased nonclassical monocytes. All identified NK-cell subsets in the severe COVID-19 group displayed increased expression of activation and tissue-resident markers, such as CD69 (cluster of differentiation 69). We observed significant correlations between altered immune subsets and plasma oxidized-low-density lipoprotein levels. In vitro assays revealed increased uptake of oxidized-low-density lipoprotein into monocyte-derived macrophages in the presence of NK cells activated by plasma of patients with severe COVID-19. Transcriptome analyses confirmed enriched proinflammatory responses and lipid dysregulation associated with epigenetic modifications in monocytes and NK cells during severe COVID-19.

conclusionsOur study provides new insights into the involvement of monocytes and NK cells in the increased CVD risk observed during and after COVID-19.

Indexed as

BiomarkersCardiovascular DiseasesCOVID-19Killer Cells, NaturalMonocytesSARS-CoV-2AdultAgedCase-Control StudiesCells, CulturedFemaleHeart Disease Risk FactorsHumansLipoproteins, LDLMaleMiddle AgedBiomarkersLipoproteins, LDLoxidized low density lipoproteinatherosclerosiscardiovascular diseaseskiller cells, naturalmonocytesSARS-CoV-2

Identifiers

PMID38989579
PMCPMC11448863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.